A four-miRNA signature in serum as a biomarker for bladder cancer diagnosis.

Rongkang Li,

Xuan Chen, Xinji Li

et al.

PubMed, Journal Year: 2022, Volume and Issue: 14(7), P. 4606 - 4616

Published: Jan. 1, 2022

Urinary bladder cancer (BCa) is globally the 10th most frequent cancer. As a novel diagnostic tool, miRNA in serum screening non-invasive. This project aimed to determine particular miRNAs as biomarkers for diagnosing urinary BCa.We designed three-phase study with 122 healthy controls (HCs) and 132 BCa patients. The 30 miRNAs' expressions from HCs patients were detected during phase. dysregulation tested training (HCs vs. BCa, each) validation (80 82 BCa) phase further. ability of these candidate was estimated by receiver operating characteristic (ROC) curves well area under ROC curve (AUC). target genes their annotations functions predicted utilizing bioinformatic assays.Six (miR-124-3p, miR-182-5p, miR-1-3p, miR-196a-5p, miR-23b-3p miR-34a-5p) had significantly different expression between four-microRNA panel improved value, AUC =0.985. result analysis showed that may be related MAPK signaling pathway cancer.Our identified four-miRNA non-invasive new biomarker BCa.

Language: Английский

A Liquid Biopsy in Bladder Cancer—The Current Landscape in Urinary Biomarkers DOI Open Access
Milena Matuszczak,

Adam Kiljańczyk,

Maciej Salagierski

et al.

International Journal of Molecular Sciences, Journal Year: 2022, Volume and Issue: 23(15), P. 8597 - 8597

Published: Aug. 2, 2022

The non-muscle invasive bladder cancer tends to recur and progress. Therefore, it requires frequent follow-ups, generating costs making one of the most expensive neoplasms. Considering character current gold-standard diagnostic procedure, white-light cystoscopy, efforts find an alternative method are ongoing. Although last decade has seen significant advancements in urinary biomarker tests (UBTs) for cancer, international guidelines have not recommended them. Currently, paramount urgency is validate test with best specificity sensitivity, which would allow optimizing diagnosis, prognosis, a treatment plan. This review aims summarise up-to-date state knowledge relating UBTs new developments detection, surveillance their potential applications clinical practice.

Language: Английский

Citations

42
Extracellular vesicles in cancer: challenges and opportunities for clinical laboratories DOI
Álvaro González, Silvia López-Borrego, Amaia Sandúa

et al.

Critical Reviews in Clinical Laboratory Sciences, Journal Year: 2024, Volume and Issue: 61(6), P. 435 - 457

Published: Feb. 15, 2024

Extracellular vesicles (EVs) are nano-sized particles secreted by most cells. They transport different types of biomolecules (nucleic acids, proteins, and lipids) characteristic their tissue or cellular origin that can mediate long-distance intercellular communication. In the case cancer, EVs participate in tumor progression modifying microenvironment, favoring immune tolerance metastasis development. Consequently, have great potential liquid biopsy for cancer diagnosis, prognosis follow-up. addition, could a role treatment as targeted drug delivery system. The intense research EV field has resulted hundreds patents creation biomedical companies. However, methodological issues heterogeneity composition hampered advancement validation trials development EV-based diagnostic therapeutic products. only few biomarkers moved from to clinical laboratories, such ExoDx Prostate IntelliScore (EPI) test, CLIA/FDA-approved prostate test. number large-scale multicenter studies would clearly define biomarker performance is limited. this review, we will critically describe EVs, methods enrichment characterization, biological cancer. Then, specially focus on parameters be considered translation biology clinic laboratory, advances already made related diagnosis treatment, still pending solved before used routine tool oncology.

Language: Английский

Citations

9
Urinary extracellular vesicles-encapsulated miRNA signatures: A new paradigm for urinary bladder cancer diagnosis and classification DOI
Sukhad Kural, Garima Jain, Sakshi Agarwal

et al.

Urologic Oncology Seminars and Original Investigations, Journal Year: 2024, Volume and Issue: 42(7), P. 179 - 190

Published: April 8, 2024

Language: Английский

Citations

9
Exosomal noncoding RNAs as noninvasive biomarkers in bladder cancer: a diagnostic meta-analysis DOI Creative Commons
Liming Zhao, Jun Li,

Zhongguang Xue

et al.

Clinical & Translational Oncology, Journal Year: 2024, Volume and Issue: 26(6), P. 1497 - 1507

Published: Jan. 16, 2024

Abstract Background In view of discordance consisting in different reports, a meta-analysis was conducted to comprehensively evaluate the diagnostic efficacy exosomal noncoding RNAs (ncRNAs) blood and urine detection bladder cancer. Methods Eligible studies were acquired by systematic retrieval through PubMed, Cochrane Library, Embase. The pooled appraised reckoning area under summary receiver operating characteristic (SROC) curve. latent sources heterogeneity probed subgroup analyses meta-regression. STATA 12.0, Meta-DiSc 1.4, RevMan 5.3 applied carry out all statistical plots. Results A total 46 from 15 articles comprising 2622 controls 3015 cancer patients included our meta-analysis. Exosomal ncRNAs represented relatively satisfactory detecting cancer, with sensitivity 0.75, specificity 0.79, an SROC curve (AUC) 0.84. microRNAs (miRNAs) exhibited better value AUC 0.91 than that long (lncRNAs). To some extent, among induced ncRNA types (miRNA or lncRNA), profiling (single- multiple-ncRNA), sample size, specimen types, ethnicity. Conclusion may play vital role diagnosing as prospective noninvasive biomarkers; nonetheless, their clinical performance needs be confirmed further massive proactive researches.

Language: Английский

Citations

6
Crosstalk of miRNAs with signaling networks in bladder cancer progression: Therapeutic, diagnostic and prognostic functions DOI
Mehrdad Hashemi, Hamid Zaferani Arani,

Sima Orouei

et al.

Pharmacological Research, Journal Year: 2022, Volume and Issue: 185, P. 106475 - 106475

Published: Oct. 3, 2022

Language: Английский

Citations

21
Urinary miRNAs as a Diagnostic Tool for Bladder Cancer: A Systematic Review DOI Creative Commons
Anna Grimaldi,

Cristina Lapucci,

Marco Salvatore

et al.

Biomedicines, Journal Year: 2022, Volume and Issue: 10(11), P. 2766 - 2766

Published: Oct. 31, 2022

Bladder cancer is the 10th most common type worldwide. Cystoscopy represents gold standard for bladder diagnosis, but this procedure invasive and painful, hence need to identify new biomarkers through noninvasive procedures. microRNAs (miRNAs) are considered be promising diagnostic molecules, because they very stable in biological fluids (including urine) easily detectable. This systematic review analyses power of urine miRNAs as markers. We conducted according Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) statement. A total 293 records related their significance BC were retrieved from PubMed Embase databases. search literature was performed, a 25 articles (N = 4054 participants) identified reviewed. Although many selected studies high scientific quality, results proved quite heterogeneous, we did not univocal consensus specific miRNA signature only isolated signatures. signatures, some them with better compared others.

Language: Английский

Citations

20
Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications DOI Open Access
Siyu Wu, Rong Li,

Yuan‐Hong Jiang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 165, P. 115027 - 115027

Published: June 22, 2023

The types of urothelial carcinoma (UC) include bladder cancer and upper tract carcinoma. Current diagnostic techniques cannot meet the needs patients. Liquid biopsy is an accurate method determining molecular profile UC a cutting-edge popular technique that expected to complement existing detection benefit patients with UC. Circulating tumor cells, cell-free DNA, RNA, extracellular vesicles, proteins, metabolites can be found in blood, urine, or other bodily fluids are examined during liquid biopsies. This article focuses on components biopsies their clinical applications have tremendous potential multiple aspects precision oncology, from early diagnosis treatment monitoring predicting prognoses. They may therefore play important role management medicine.

Language: Английский

Citations

12
Effects of Exosomes on Tumor Bioregulation and Diagnosis DOI Creative Commons
Tong Wu, Ying Liu,

Nasra Mohamoud Ali

et al.

ACS Omega, Journal Year: 2023, Volume and Issue: 8(6), P. 5157 - 5168

Published: Jan. 31, 2023

Exosomes are lipid bilayer vesicles in biological fluids, which can participate processes by mediating intercellular communication and activating intracellular signaling pathways, especially cancerogenic processes, such as proliferation, metastasis, invasion, immune regulation of cancer cells. Besides, cancer-derived exosomes also involved tumor diagnosis therapy biomarkers nanotransport devices. This article reviews the latest research progress on disease tumors, with aim providing new ideas for clinical treatment cancers.

Language: Английский

Citations

11
Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer DOI

Jiaxin Zhao,

Jinming Li, Rui Zhang

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2023, Volume and Issue: 1878(4), P. 188926 - 188926

Published: May 24, 2023

Language: Английский

Citations

11
Urine‐based liquid biopsy in bladder cancer: Opportunities and challenges DOI Creative Commons
Gang Wang, Wan Jin,

Zilin Xu

et al.

Clinical and Translational Discovery, Journal Year: 2023, Volume and Issue: 3(1)

Published: Feb. 1, 2023

Abstract Bladder cancer (BLCA) is a most common urological tumours with high rate of recurrence, which needs long‐term follow‐up. To date, diagnosis and surveillance BLCA still rely on cystoscopy, an invasive expensive method that increases the difficulty for routine Therefore, exploring new biomarkers or tests effective way to improve current clinical management BLCA. Recent years, liquid biopsy has received increasing attention, especially its great potential application in non‐invasive detection tumours. In addition, involves wide range biomarkers, including DNA, RNA, proteins, extracellular vesicles metabolites blood, urine other body fluids. For BLCA, ideal fluid achieve surveillance. Here, we address recent developments urine‐based diagnostic challenges such as early detection, minimal residual, recurrence monitoring therapeutic response. Meanwhile, many need be overcome are also discussed.

Language: Английский

Citations

10